Host Cell Protein Detection and Monitoring Using LC-MS
Enhance your Host Cell Protein analysis beyond the capabilities of commercial ELISA kits. Our advanced methods allow you to:
- Identify and relatively quantify individual HCPs at various stages of your process development and manufacturing using SWATH® Mass Spectrometry expertise.
- Track problematic HCPs through purification stages and develop robust removal strategies with customizable MS-based approaches for various host cells, including E. coli, CHO cells, yeast, and HEK cells.
- Mitigate the risks of process changes (e.g. manufacturing site change or scale-up) through characterization of your cell lysate, allowing HCP profile comparisons.
- Utilize a fast, cost-effective method for when no commercial kit is available. Our rapid turnaround times accelerate your development timeline without compromising data quality or regulatory compliance.
- Accurate quantitation of individual HCPs of specific interest, including high risk proteins (e.g. Phospholipase B-like 2 (PLBL-2), Lipoprotein lipase, clusterin).
Why Use Biopharmaspec For HCP Analysis
- Advanced Instrumentation Without the Capital Cost: By partnering with BioPharmaSpec, you gain access to powerful LC-MS platforms — including Q-TOF and Triple Quadrupole MS systems — without the need to invest in, maintain, or operate complex instrumentation in-house. Our laboratory infrastructure is ready to support your development projects at any stage.
- Deep Expertise in HCP Characterization: Our team of highly experienced scientists brings decades of expertise in mass spectrometry-based impurity analysis. This ensures not only precise operation of the instrumentation but also expert interpretation of complex datasets, delivering accurate, high-confidence results.
- Custom Strategies to Meet Your Process Needs: We recognize that every biopharmaceutical process is different. Whether you're working with CHO cells, E. coli, yeast or HEK systems, we tailor our HCP analysis strategies to your specific expression system and development goals — from qualitative screening to targeted quantitation of high-risk proteins such as PLBL2 or clusterin.
- International Laboratory Network: Wherever you are, BioPharmaSpec offers access to high-quality analytical services through our labs in the United States, United Kingdom, Germany, Italy, and Lithuania.
What are Host Cell Proteins?
Host Cell Proteins (HCPs) are endogenous impurities from the cell lines used to produce biopharmaceuticals. Their presence in the drug product can cause decreased stability, increased immunogenicity and increased toxicity to patients, posing serious safety risks. Although purification processes reduce HCP levels, some residual HCPs often remain, necessitating continuous monitoring throughout the production process.
Acceptable Limits of Host Cell Protein
Regulatory agencies evaluate acceptable ELISA- detected HCP limits on a case-by-case basis. Most companies target total HCP levels below 100 ng/mg (100 ppm). However, even at low levels, unknown HCPs can cause an undesirable immune response or impact the product functionality, making comprehensive HCP characterization and monitoring critical. This aligns with regulatory guidelines such as US (21 CFR 610.13, USP 1132.1), European (ICH Q6B, EMA 3AB1a) and others.
Download Our HCP Technical Bulletin
HCP Analysis by Mass Spectrometry: An Orthogonal Method to Enhance Your ELISA Data
BioPharmaSpec has developed a service for MS based HCP detection and quantitation as an orthogonal support to HCP-ELISA. The service is set up as a phased approach, giving you complete control and built-in 'stop-go' decision points.
Mass Spectrometry (MS) complements ELISA kits by identification and relative or absolute quantification of individual HCPs present in your product throughout your process, providing a broader detection scope than ELISA alone.
Armed with this knowledge, you can track host cell protein contaminants of concern, such as enzymatic or immunogenic proteins, through your purification process, demonstrating a reduction at each step, and develop robust strategies for removing them.
On-Demand Webinar: Host Cell Protein Analysis by MS
Discover how LC-MS can enhance your HCP strategy beyond the limits of ELISA. This expert-led webinar explores orthogonal detection techniques, library generation, software tools, and when to apply HCP-MS in development. Ideal for scientists in development, QC, and downstream processing.
Client Case Study: HCP Quantification with LC-MS
Explore BioPharmaSpec’s phased approach to Host Cell Protein analysis using LC-MS. This publication features real-life client data and outlines how mass spectrometry can be used to both identify and quantify HCPs with precision across development stages.
No Commercial Kit Available?
For products without commercial kits, MS methods are a fast, economical and flexible alternative to developing product-specific ELISAs. Unlike HCP-ELISA, which relies on polyclonal antibodies, MS approaches detect a wider range of host cell proteins in a de novo manner, without needing specialized reagents or product/process specific method development.
The Benefits of LC-MS and ELISA Together
Supplementing ELISA with LC-MS offers a synergistic approach: ELISA provides initial screening and relative quantification, while MS offers detailed identification, absolute quantification and broad coverage of host cell proteins. This dual-method strategy ensures thorough HCP analysis from discovery onwards.
| Detection Coverage | Detects and quantifies a wide range of individual HCPs | Limited to detection of HCPs targeted by available antibodies. |
| Specificity | Identifies HCPs based on peptide sequence matches, and may miss certain HCPs. | Based on antibody coverage used in the assay, may miss certain HCPs. |
| Flexibility | Adaptable to various biopharmaceutical products and expression systems. | Requires development of specific assays for each biopharmaceutical product. |
| Speed | Rapid turnaround times, suitable for fast-paced development. | Development time can be lengthy (months to years) for product-specific assays. |
| Quantification | Can provide absolute quantification of HCPs using synthetic analogues. | Semi-quantitative, provides relative levels based on standard curves. |
| Comprehensive Analysis | Identifies process-related protein impurities beyond known HCPs, essential for risk assessment. | Limited to known impurities targeted by specific antibodies. |
The BioPharmaSpec Approach to Host Cell Protein Analysis
BioPharmaSpec’s MS-based HCP detection service supports HCP-ELISA and follows a phased approach:
- IDA analysis of cell extract (lysate), mid-purification process sample or final drug product.
- Screened against a database(s).
- IDA analysis of samples. Screened against a database.
- DIA analysis of samples. Screened against the Ion Library.
- High-risk HCPs can be identified and targeted for future monitoring.
- Known internal protein spikes are used to quantitate HCPs.
- Changes in the quantity of HCPs are monitored for each sample.
- HCP amounts can be compared against ELISA levels for orthogonal verification.
- HCP peptides of interest in the final drug product are chosen for absolute quantitation.
- Cold heavy-labeled peptides are used to quantitate using MRM.
Detailed Approach
Start Using LC-MS for Better HCP Detection and Monitoring
Whether you want to ensure a robust control strategy of your recombinant protein or monoclonal antibody, gain a better process understanding or compare HCP profiles throughout your process and in the final product, contact us today to find out how you can quickly start using LC-MS in your development projects.